ASX ANNOUNCEMENT **19 DECEMBER 2023**

ADVENT-AML CLINICAL TRIAL GMP MANUFACTURING COMPLETE

- Manufacturing of CHM 0201 NK cells to support ADVENT-AML clinical trial complete
- ADVENT-AML Phase 1B clinical trial in Acute Myeloid Leukemia to be initiated at The University of Texas MD Anderson Cancer Center

Sydney, Australia, 19 December 2023: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce the completion of GMP manufacturing of CHM 0201 NK cells to support the ADVENT-AML Phase 1B clinical trial in which Chimeric's off-the-shelf universal donor NK cell therapy will be evaluated in combination with standard of care therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).

CHM 0201 NK cells have completed GMP manufacturing and release testing and are in transit to The University of Texas MD Anderson Cancer Center for initiation of the ADVENT-AML Phase 1B clinical trial. The CHM 0201 NK cells were manufactured at the Cellular Therapy Integrated Services Laboratory at Case Western Reserve University where the CHM 0201 cells were developed. All manufacturing met specification and all release testing has now been completed.

The CHM 0201 NK cells will be studied in combination with standard of care therapy, Azacitidine and Venetoclax, in the ADVENT-AML Phase 1B clinical trial. The ADVENT-AML (NCT05834244) Phase 1B clinical trial is designed to enroll up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following completion of a dose confirmation cohort assessing the safety of this novel combination treatment in subjects with relapsed or refractory AML.

The ADVENT-AML study will be the first to evaluate the synergy of NK cell therapy in combination with the current standard of care for AML patients. It is being conducted at the University of Texas MD Anderson Cancer Center under the direction of Principal Investigator, Abhishek Maiti MD, Assistant Professor in the Department of Leukemia at MD Anderson. The trial has received FDA IND and MDACC IRB clearance and is scheduled to begin enrollment in late 2023 with only nominal funding from Chimeric.

"MD Anderson is a global leader in cancer research with one of the largest clinical programs for the management of patients with AML in the United States," said Jennifer Chow, Chief Executive Officer of Chimeric Therapeutics. "We are very pleased to be able to support the ADVENT-AML trial with the manufacturing and release of CHM 0201 NK cells as we believe that the novel combination of CHM 0201 and Azacitidine and Venetoclax has the potential to significantly enhance the outcomes for AML patients."

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase 1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au